60 Participants Needed

Educational Videos for Colorectal Cancer

(PeLear CCC Trial)

DV
JG
Overseen ByJosé G. Guillem, MD, MPH, MBA
Age: 18+
Sex: Any
Trial Phase: Academic
Sponsor: University of North Carolina, Chapel Hill
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

Trial Summary

Will I have to stop taking my current medications?

The trial information does not specify whether you need to stop taking your current medications. It seems to focus on educational sessions rather than medical treatments.

What data supports the effectiveness of the treatment Colorectal Cancer Educational Videos in Spanish?

Research on educational videos for other types of cancer, like breast and prostate cancer, shows that these videos can improve patients' understanding of their condition and help them make better treatment decisions. Additionally, a study on a colorectal cancer video for the Somali community suggests that culturally adapted videos can increase knowledge and participation in cancer screening.12345

Is it safe to use educational videos for colorectal cancer information?

Educational videos for colorectal cancer are generally safe as they are designed to improve patient knowledge and communication with healthcare providers. They have been well-received by diverse patient groups and medical professionals, with no safety concerns reported in the studies.46789

How do educational videos for colorectal cancer differ from other treatments?

Educational videos for colorectal cancer are unique because they focus on increasing patient knowledge and communication about screening, rather than directly treating the disease. They are designed to overcome barriers to screening by providing culturally appropriate and easy-to-understand information, which can help patients make informed decisions about their health.610111213

What is the purpose of this trial?

The study aims to recruit 60 Spanish speaking individuals who identify as Latinos, are 18 years or older and attend the Saint Thomas More (STM) Church in Chapel Hill. Study participants will be asked to attend an educational session at STM Church during which their baseline knowledge on colorectal cancer (CRC) and willingness to participate in cancer clinical trials (CCT) will be assessed through a questionnaire in Spanish. Following this, participants will watch three educational videos on CRC in Spanish. After watching the videos, CRC knowledge and willingness to participate in CCTs will be reassessed. Thirty +/- 7 days after participation in the educational session, participants will be invited back at STM Church in order to complete a follow-up questionnaire assessing CRC knowledge, willingness to participate in CCTs and perceived barriers preventing Latinos from participating in CCTs. Twenty of the 60 recruited participants will be asked to participate in a qualitative one-on-one interview aimed at identifying barriers preventing Latinos from participating in CCTs.It should be noted that cancer is the leading cause of death in the United States (US) Latino community, with CRC accounting for 10% of this overall mortality. Despite this, Latinos suffer from disparities in access to care, cancer screening, treatment, and representation in CCTs. In fact, although Latino individuals are among the largest and fastest growing communities of color in the US, currently comprising 18.7%, their representation in CCTs remains low. This is of concern because: 1) advances arising from trials with limited Latino representation may not be applicable to the Latino population, and 2) decreased Latino participation in CCTs may delay Latino access to novel therapies in a timely fashion. The investigators conducting this study believe that low cancer-specific health knowledge may be impacting Latino representation and willingness to participate in CCTs and can be addressed through culturally and linguistically appropriate community-based educational interventions. Latino CCT underrepresentation is a multifaceted phenomenon and bidirectional barriers at the physician-, healthcare system-, and patient-level are significant contributors. Therefore, understanding the multiple driving forces and barriers is essential to identifying potential targets for improvement.

Research Team

JG

José G. Guillem, MD, MPH, MBA

Principal Investigator

University of North Carolina, Chapel Hill

Eligibility Criteria

The PeLear CCC trial is for Spanish-speaking Latinos over 18 years old, aiming to increase colorectal cancer knowledge and participation in clinical trials. It's specifically for those attending Saint Thomas More Church in Chapel Hill.

Inclusion Criteria

I am older than 18 years old.
Identifying as Latino
I speak Spanish.

Exclusion Criteria

Not identifying as Latino
I am under 18 years old.
I do not speak Spanish.

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Educational Intervention

Participants attend an educational session at STM Church, complete a baseline questionnaire, watch three educational videos on CRC, and complete a post-video questionnaire.

1 day
1 visit (in-person)

Follow-up

Participants return to STM Church to complete a follow-up questionnaire assessing CRC knowledge, willingness to participate in CCTs, and perceived barriers.

4-5 weeks
1 visit (in-person)

Qualitative Interviews

Twenty participants participate in one-on-one interviews to identify barriers to CCT participation.

1 day
1 visit (in-person)

Treatment Details

Interventions

  • Colorectal Cancer Educational Videos in Spanish
Trial Overview This study tests the effectiveness of educational videos on colorectal cancer awareness among Latinos. Participants will complete questionnaires before and after viewing the videos to measure changes in knowledge and willingness to join clinical trials.
Participant Groups
1Treatment groups
Experimental Treatment
Group I: Educational VideosExperimental Treatment1 Intervention
Enrolled participants will watch three educational videos in Spanish pertaining to: (1) Colorectal Cancer (CRC) symptoms; (2) CRC risk factors and (3) CRC facts, screening, treatment, and Cancer Clinical Trials (CCT).

Find a Clinic Near You

Who Is Running the Clinical Trial?

University of North Carolina, Chapel Hill

Lead Sponsor

Trials
1,588
Recruited
4,364,000+

North Carolina Translational and Clinical Sciences Institute

Collaborator

Trials
61
Recruited
4,600+

Findings from Research

This pilot study involving 28 newly diagnosed breast cancer patients found that personalized video education prior to their first oncology consultation is feasible and may enhance understanding of their specific diagnosis, particularly regarding tumor subtype.
While patients receiving personalized videos showed improvements in perceived understanding and decision-making, the overall differences between personalized video education and standard materials were not statistically significant, indicating the need for further research to optimize educational approaches.
Evaluating the Effect of a Video Education Curriculum for First Time Breast Cancer Patients: a Prospective RCT Feasibility Study.Sulakvelidze, N., Burdick, B., Kaklamani, V., et al.[2020]
A video intervention significantly increased knowledge about prostate cancer screening and treatment among 52 patients in the experimental group, compared to no change in the control group, indicating its effectiveness as an educational tool.
The video also influenced patients' preferences for prostate-specific antigen (PSA) screening, with 31% of the experimental group changing their preference compared to only 2% in the control group, demonstrating its impact on patient decision-making without causing confusion or fear.
Efficacy of a video for teaching patients about prostate cancer screening and treatment.Ruthman, JL., Ferrans, CE.[2018]
The video intervention 'Telling the Story ... To Live is God's Will' significantly reduced cancer fatalism and increased knowledge about colorectal cancer among participants aged 52-92, compared to a control group that viewed a different video.
Both the intervention and control groups had over 60% participation in fecal-occult blood testing (FOBT), indicating that the video intervention was effective in promoting screening behaviors while also addressing underlying beliefs about cancer.
An intervention to decrease cancer fatalism among rural elders.Powe, BD., Weinrich, S.[2022]

References

Evaluating the Effect of a Video Education Curriculum for First Time Breast Cancer Patients: a Prospective RCT Feasibility Study. [2020]
Efficacy of a video for teaching patients about prostate cancer screening and treatment. [2018]
An intervention to decrease cancer fatalism among rural elders. [2022]
A Culturally Adapted Colorectal Cancer Education Video for the Somali Community in Minnesota: A Pilot Investigation. [2022]
The Effect of Previsit Education in Breast Cancer Patients: A Study of a Shared-decision-making Tool. [2016]
Development Of An Educational Video To Improve Patient Knowledge And Communication With Their Healthcare Providers About Colorectal Cancer Screening. [2022]
Evaluation of the addition of video-based education for patients receiving standard pre-chemotherapy education. [2019]
Current Quality of Videos on Colorectal Cancer Screening for General Public. [2023]
Feasibility trial of a Spanish-language multimedia educational intervention. [2021]
A multimedia patient education program on colorectal cancer screening increases knowledge and willingness to consider screening among Hispanic/Latino patients. [2021]
The right colon challenge. [2018]
YouTube Videos as a Source of Information on Colorectal Cancer: What Do Our Patients Learn? [2022]
Engaging the community served: a U.S. Cancer Center's Facebook live cancer awareness campaign for Spanish-speaking Latinos during COVID-19. [2023]
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security